PDCD1 and neoplasm: Recently, a completed phase I clinical trial used CRISPR‐Cas9 system to knock out the endogenous TCRs and PD1 genes of autologous T cells.[89] These CRISPR edited T cells induced durable anti‐tumor effect with good tolerance in patients with refractory cancers.